Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate‐to‐severe facial acne vulgaris: A phase 3, multi‐centre, randomized, double‐blind, vehicle‐controlled study

Abstract Background FMX101 4%, as a topical foam formulation of minocycline, has been approved by US Food and Drug Administration for the treatment of moderate‐to‐severe acne vulgaris (AV). Objective To evaluate the efficacy and safety of FMX101 4% in treating Chinese subjects with moderate‐to‐severe facial AV. Methods This was a multi‐centre, randomized, double‐blind, vehicle‐controlled phase 3 study in Chinese subjects with moderate‐to‐severe AV. Eligible subjects were randomized 2:1 to receive either FMX101 4% or vehicle foam treatment for 12 weeks. The primary efficacy endpoint was the change in inflammation lesion count (ILC) from baseline at week 12. The key secondary endpoint was the treatment success rate according to Investigator's Global Assessment (IGA) at week 12. Results In total, 372 subjects were randomized into two groups (FMX101 4% group, n = 248; vehicle group, n = 124). After 12 weeks treatment, the reduction in ILC from baseline was statistically significant in favour of FMX101 4%, compared with vehicle foam (−21.0 [0.08] vs. −12.3 [1.14]; LSM [SE] difference, −8.7 [1.34]; 95% CI [−11.3, −6.0]; p < 0.001). FMX101 4% treatment yielded significantly higher IGA treatment success rate at week 12 as compared to the control treatment (8.06% vs. 0%). Applying FMX101 4% also resulted in significant reduction in noninflammatory lesion count (nILC) versus vehicle foam at week 12 (−19.4 [1.03] vs. −14.9 [1.47]; LSM [SE] difference, −4.5 [1.74]; 95% CI [−8.0, −1.1]; p = 0.009). Most treatment‐emergent adverse events (TEAEs) were mild‐to‐moderate in severity, and no treatment‐related treatment‐emergent serious adverse event (TESAE) occurred. Thus, FMX101 4% was considered to be a safe and well‐tolerated product during the 12‐week treatment period. Conclusions FMX101 4% treatment for 12 weeks could lead to significantly reduced ILC and nILC, and improved IGA treatment success rate in Chinese subjects with moderate‐to‐severe facial AV. It also showed a well acceptable safe and tolerability profile.